Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial
Background: In vitro studies have shown that several oral antiseptics have virucidal activity against SARS-CoV-2. Thus, mouthwashes have been proposed as an easy to implement strategy to reduce viral transmission. However, there are no data measuring SARS-CoV-2 viability after mouthwashes in vivo. M...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2022.2098059 |
| _version_ | 1811311548073771008 |
|---|---|
| author | Álvaro Sánchez Barrueco María Victoria Mateos-Moreno Yolanda Martínez-Beneyto Elisa García-Vázquez Alfonso Campos González Javier Zapardiel Ferrero Abel Bogoya Castaño Ignacio Alcalá Rueda José Miguel Villacampa Aubá Carlos Cenjor Español Laura Moreno-Parrado Verónica Ausina-Márquez Sandra García-Esteban Alejandro Artacho F. Xavier López-Labrador Alex Mira María D. Ferrer |
| author_facet | Álvaro Sánchez Barrueco María Victoria Mateos-Moreno Yolanda Martínez-Beneyto Elisa García-Vázquez Alfonso Campos González Javier Zapardiel Ferrero Abel Bogoya Castaño Ignacio Alcalá Rueda José Miguel Villacampa Aubá Carlos Cenjor Español Laura Moreno-Parrado Verónica Ausina-Márquez Sandra García-Esteban Alejandro Artacho F. Xavier López-Labrador Alex Mira María D. Ferrer |
| author_sort | Álvaro Sánchez Barrueco |
| collection | DOAJ |
| description | Background: In vitro studies have shown that several oral antiseptics have virucidal activity against SARS-CoV-2. Thus, mouthwashes have been proposed as an easy to implement strategy to reduce viral transmission. However, there are no data measuring SARS-CoV-2 viability after mouthwashes in vivo. Methods: In this randomized double-blind, five-parallel-group, placebo-controlled clinical trial, SARS-CoV-2 salivary viral load (by quantitative PCR) and its infectious capacity (incubating saliva in cell cultures) have been evaluated before and after four different antiseptic mouthwashes and placebo in 54 COVID-19 patients. Results: Contrary to in vitro evidence, salivary viral load was not affected by any of the four tested mouthwashes. Viral culture indicated that cetylpyridinium chloride (CPC) significantly reduced viral infectivity, but only at 1-hour post-mouthwash. Conclusion: These results indicate that some of the mouthwashes currently used to reduce viral infectivity are not efficient in vivo and, furthermore, that this effect is not immediate, generating a false sense of security.Trial registration: ClinicalTrials.gov identifier: NCT04707742.. |
| first_indexed | 2024-04-13T10:20:58Z |
| format | Article |
| id | doaj.art-aa9a0836292448708bc70df22bb9f329 |
| institution | Directory Open Access Journal |
| issn | 2222-1751 |
| language | English |
| last_indexed | 2024-04-13T10:20:58Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj.art-aa9a0836292448708bc70df22bb9f3292022-12-22T02:50:31ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512022-12-011111833184210.1080/22221751.2022.2098059Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trialÁlvaro Sánchez Barrueco0María Victoria Mateos-Moreno1Yolanda Martínez-Beneyto2Elisa García-Vázquez3Alfonso Campos González4Javier Zapardiel Ferrero5Abel Bogoya Castaño6Ignacio Alcalá Rueda7José Miguel Villacampa Aubá8Carlos Cenjor Español9Laura Moreno-Parrado10Verónica Ausina-Márquez11Sandra García-Esteban12Alejandro Artacho13F. Xavier López-Labrador14Alex Mira15María D. Ferrer16ENT and Cervicofacial Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid, SpainDepartment of Dental Clinical Specialties, School of Dentistry, Madrid Complutense University, Madrid, SpainDepartment of Dermatology, Stomatology and Radiology, University of Murcia, Murcia, SpainInfectious Diseases Unit, Virgen de la Arrixaca University Clinical Hospital, IMIB, Murcia, SpainENT and Cervicofacial Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid, SpainMicrobiology Department, Fundación Jiménez Díaz University Hospital, Madrid, SpainENT and Cervicofacial Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid, SpainENT and Cervicofacial Surgery Department, Villalba General University Hospital, Collado Villalba, SpainENT and Cervicofacial Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid, SpainENT and Cervicofacial Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid, SpainMicrobiology Service, Murcian Institute of Biosanitary Research, Virgen de la Arrixaca University Clinical Hospital, Murcia, SpainDepartment of Dentistry, European University of Valencia, Valencia, SpainGenomics & Health Department, FISABIO-Public Health Foundation, Valencia, SpainGenomics & Health Department, FISABIO-Public Health Foundation, Valencia, SpainGenomics & Health Department, FISABIO-Public Health Foundation, Valencia, SpainGenomics & Health Department, FISABIO-Public Health Foundation, Valencia, SpainGenomics & Health Department, FISABIO-Public Health Foundation, Valencia, SpainBackground: In vitro studies have shown that several oral antiseptics have virucidal activity against SARS-CoV-2. Thus, mouthwashes have been proposed as an easy to implement strategy to reduce viral transmission. However, there are no data measuring SARS-CoV-2 viability after mouthwashes in vivo. Methods: In this randomized double-blind, five-parallel-group, placebo-controlled clinical trial, SARS-CoV-2 salivary viral load (by quantitative PCR) and its infectious capacity (incubating saliva in cell cultures) have been evaluated before and after four different antiseptic mouthwashes and placebo in 54 COVID-19 patients. Results: Contrary to in vitro evidence, salivary viral load was not affected by any of the four tested mouthwashes. Viral culture indicated that cetylpyridinium chloride (CPC) significantly reduced viral infectivity, but only at 1-hour post-mouthwash. Conclusion: These results indicate that some of the mouthwashes currently used to reduce viral infectivity are not efficient in vivo and, furthermore, that this effect is not immediate, generating a false sense of security.Trial registration: ClinicalTrials.gov identifier: NCT04707742..https://www.tandfonline.com/doi/10.1080/22221751.2022.2098059SARS-CoV-2salivaCOVID-19infectivitymouthwash |
| spellingShingle | Álvaro Sánchez Barrueco María Victoria Mateos-Moreno Yolanda Martínez-Beneyto Elisa García-Vázquez Alfonso Campos González Javier Zapardiel Ferrero Abel Bogoya Castaño Ignacio Alcalá Rueda José Miguel Villacampa Aubá Carlos Cenjor Español Laura Moreno-Parrado Verónica Ausina-Márquez Sandra García-Esteban Alejandro Artacho F. Xavier López-Labrador Alex Mira María D. Ferrer Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial Emerging Microbes and Infections SARS-CoV-2 saliva COVID-19 infectivity mouthwash |
| title | Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial |
| title_full | Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial |
| title_fullStr | Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial |
| title_full_unstemmed | Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial |
| title_short | Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial |
| title_sort | effect of oral antiseptics in reducing sars cov 2 infectivity evidence from a randomized double blind clinical trial |
| topic | SARS-CoV-2 saliva COVID-19 infectivity mouthwash |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2022.2098059 |
| work_keys_str_mv | AT alvarosanchezbarrueco effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT mariavictoriamateosmoreno effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT yolandamartinezbeneyto effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT elisagarciavazquez effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT alfonsocamposgonzalez effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT javierzapardielferrero effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT abelbogoyacastano effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT ignacioalcalarueda effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT josemiguelvillacampaauba effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT carloscenjorespanol effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT lauramorenoparrado effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT veronicaausinamarquez effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT sandragarciaesteban effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT alejandroartacho effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT fxavierlopezlabrador effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT alexmira effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial AT mariadferrer effectoforalantisepticsinreducingsarscov2infectivityevidencefromarandomizeddoubleblindclinicaltrial |